Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8815929 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Jan, 2024
(3 months ago) | |
US8420688 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(3 months from now) | |
US7812049 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
May, 2028
(4 years from now) | |
US8883838 | MAYNE PHARMA | Pharmaceutical cream compositions and methods of use |
Dec, 2031
(7 years from now) | |
US10751325 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
US11517560 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
US10335391 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
US9974773 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) |
Rhofade is owned by Mayne Pharma.
Rhofade contains Oxymetazoline Hydrochloride.
Rhofade has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Rhofade are:
Rhofade was authorised for market use on 18 January, 2017.
Rhofade is available in cream;topical dosage forms.
Rhofade can be used as once daily topical treatment of persistent facial erythema associated with rosacea in female adults, once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment, once daily topical treatment of persistent facial erythema associated with rosacea in adults, topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream.
The generics of Rhofade are possible to be released after 11 June, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 18, 2020 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with ...
Dosage: CREAM;TOPICAL